Stelexis Biosciences
- Biotech or pharma, therapeutic R&D
Two first-in-class or best-in-class precision medicines entering the clinic for patients with AML and MDS between 2Q25 and 4Q25. Up to 8 clinical proof-of-concept data-readouts between 4Q25 and 4Q27.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}